Welcome to our dedicated page for ENvue Medical SEC filings (Ticker: FEED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ENvue Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ENvue Medical's regulatory disclosures and financial reporting.
ENvue Medical, Inc. disclosed that shareholder Christian Michael Glibert has fully exited his position in the company’s common stock. On June 22, 2026, he sold his remaining 210,000 shares in open market trades at a weighted average price of $0.6880 per share, with prices ranging from $0.6756 to $0.7220. Following these sales, he beneficially owns 0 shares, representing 0.0% of ENvue’s outstanding common stock, and reports no contracts or arrangements related to the company’s securities.
ENvue Medical, Inc. insider Christian Michael Glibert reported an open-market sale of 210,000 shares of Common Stock at an average price of $0.688 per share. The sale was executed in multiple transactions with prices ranging from $0.6756 to $0.722. Following this transaction, the filing shows that Glibert directly holds 0 shares of ENvue Medical common stock.
ENvue Medical, Inc. registers for resale up to 6,000,768 shares of common stock issuable upon conversion of 6,254 shares of Series H Convertible Preferred Stock at a current conversion price of $1.0422 per share. The resale is by the selling stockholder and the company will receive no proceeds from such sales.
The prospectus states the shares were issued under a private placement and Additional Investment Right tied to a Purchase Agreement dated July 18, 2025. As of April 30, 2026, there were 5,246,513 shares outstanding; the conversion at maximum would substantially increase outstanding shares. The filing lists permitted resale methods and notes Nasdaq listing risks, including past bid-price and equity compliance actions.
ENvue Medical, Inc. registers the resale by a selling stockholder of up to 6,000,768 shares of common stock issuable upon conversion of 6,254 shares of Series H Convertible Preferred Stock at a current conversion price of $1.0422. The company will not receive proceeds from resales. As of April 30, 2026, 5,246,513 shares were outstanding; issuance of the full Conversion Shares would represent approximately 53.4% of outstanding shares as of that date. The prospectus notes Nasdaq listing risks, anti-dilution mechanics, cumulative dividend terms on the Series H, and broad resale methods permitted for the selling holder.
ENvue Medical, Inc. reported a significantly weaker quarter for the three months ended March 31, 2026, with revenues of $653,000 compared with $1,025,000 a year earlier, mainly due to the removal of its higher-margin PainShield Ultra product from the market.
The company generated a gross loss of $55,000 versus a gross profit of $369,000 last year, as margins were pressured by inventory write-downs and amortization of intangibles from the ENvue merger. Operating expenses rose to $3.7 million, driven by higher selling, marketing, and general and administrative costs tied to integrating and commercializing ENvue’s enteral feeding systems.
Net loss widened to $3.8 million, while net loss available to common stockholders reached $22.6 million after recognizing large deemed dividends and down-round adjustments on Series H preferred stock. Cash and cash equivalents fell to $2.2 million, with $4.3 million used in operating activities during the quarter, and the company discloses substantial doubt about its ability to continue as a going concern without additional financing.
ENvue Medical, Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The company stated it needs additional time to prepare and analyze supporting documentation and anticipates filing the Form 10-Q no later than the fifth calendar day following the prescribed due date. The notice was signed by CEO Doron Besser, M.D. on May 15, 2026.
ENvue Medical, Inc. insider Christian Michael Glibert filed a Form 4 showing no change in his share count, while his beneficial ownership percentage dropped below 10 percent. He continues to hold 240,000 shares of Common Stock directly. The footnote explains that his reduced percentage resulted from dilution after ENvue issued additional shares in connection with a merger described in its Form 10-K, meaning no shares were acquired or disposed of by him.
Christian Michael Glibert reports an updated beneficial ownership position in ENvue Medical, Inc. common stock. He continues to hold 240,000 shares, which now represent 6.5% of the company’s outstanding common stock.
The change in percentage results from ENvue Medical’s total shares outstanding increasing from 1,088,192 to 3,700,908, as disclosed in the company’s Annual Report on Form 10‑K filed on April 15, 2026. Glibert has not acquired or disposed of any shares since his initial Schedule 13D filed on February 11, 2026 and states he holds the position for investment purposes, while reserving the option to buy or sell shares in the future depending on market conditions.